, Microbial IC95 Subject Result, évalués étaient contrôlés à J21, soit 63% (IC95% : 55.9-69.7%), 2020.

, Taux d'emploi des titulaires de doctorat et des autres diplômés de l'enseignement supérieur (ES), 2012, En comparant le groupe des PB légères et modérées versus le groupe des PB sévères, le taux de contrôle à J21 était de 70.45% (IC95% : 62.2-77.6%) versus 44.2% (IC95% : 31.6-57.7%), 2016.

, 5.6. En 2014, la pauvreté était la plus élevée chez les jeunes et les enfants et la plus faible chez les adultes et les personnes âgées

, Microbial IC95 Subject Result, vol.95, pp.71-86, 2020.

G. Barday, P. Moncharmont, H. Odent-malaure, and A. Benamara, Effets indésirables receveur chez les patients avec myélodysplasie et transfusés, Transfusion Clinique et Biologique, vol.24, issue.3, p.357, 2017.

D. Narbey, A. Fillet, P. Tiberghien, and R. Djoudi, Effets indésirables cardiovasculaires chez les donneurs de sang total et en aphérèse : une étude cas-témoins, Transfusion Clinique et Biologique, vol.22, issue.4, p.231, 2015.

. L'âge, 5.6. En 2014, la pauvreté était la plus élevée chez les jeunes et les enfants et la plus faible chez les adultes et les personnes âgées

D. Le-taux, effets indésirables tous grades confondus par patient était de 1.46 ± 2.2 chez les patients avec une PB légère versus 1.3 ± 1.7 chez les patients avec une PB modérée et de

P. Joly, S. Baricault, A. Sparsa, P. Bernard, C. Bédane et al., Incidence and Mortality of Bullous Pemphigoid in France, Journal of Investigative Dermatology, vol.132, issue.8, pp.1998-2004, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00729013

P. Joly, J. Roujeau, J. Benichou, C. Picard, B. Dreno et al., A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid, New England Journal of Medicine, vol.346, issue.5, pp.321-327, 2002.

C. Feliciani, P. Joly, M. F. Jonkman, G. Zambruno, D. Zillikens et al., Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology, British Journal of Dermatology, vol.172, issue.4, pp.867-877, 2015.

S. R. Parker, S. Dyson, S. Brisman, M. Pennie, R. A. Swerlick et al., Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States, Journal of the American Academy of Dermatology, vol.59, issue.4, pp.582-588, 2008.

R. L. Colbert, D. M. Allen, D. Eastwood, and J. A. Fairley, Mortality Rate of Bullous Pemphigoid in a US Medical Center, Journal of Investigative Dermatology, vol.122, issue.5, pp.1091-1095, 2004.

K. E. Brick, C. H. Weaver, C. M. Lohse, M. R. Pittelkow, J. S. Lehman et al., Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009, Journal of the American Academy of Dermatology, vol.71, issue.1, pp.92-99, 2014.

B. Cortés, E. Khelifa, L. Clivaz, S. Cazzaniga, J. H. Saurat et al., Mortality Rate in Bullous Pemphigoid: A Retrospective Monocentric Cohort Study, Dermatology, vol.225, issue.4, pp.320-325, 2012.

S. M. Langan, L. Smeeth, R. Hubbard, K. M. Fleming, C. J. Smith et al., Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study, BMJ, vol.337, issue.jul09 1, pp.a180-a180, 2008.

J. C. Roujeau, C. Lok, S. Bastuji-garin, S. Mhalla, V. Enginger et al., High Risk of Death in Elderly Patients With Extensive Bullous Pemphigoid, Archives of Dermatology, vol.134, issue.4, p.465, 1998.

K. Kridin, N. Schwartz, A. D. Cohen, and S. Zelber-sagi, Mortality in bullous pemphigoid: A systematic review and meta-analysis of standardized mortality ratios, The Journal of Dermatology, vol.45, issue.9, pp.1094-1100, 2018.

P. Joly, J. Benichou, C. Lok, M. F. Hellot, P. Saiag et al., Prediction of Survival for Patients With Bullous Pemphigoid, Archives of Dermatology, vol.141, issue.6, pp.691-699, 2005.

M. Amagai, T. Hashimoto, S. Tajima, Y. Inokuchi, N. Shimizu et al., Partial cDNA Cloning of the 230-kD Mouse Bullous Pemphigoid Antigen by Use of a Human Monoclonal Anti-Basement Membrane Zone Antibody, Journal of Investigative Dermatology, vol.95, issue.3, pp.252-259, 1990.

A. Kromminga, C. Sitaru, C. Hagel, S. Herzog, and D. Zillikens, Development of an ELISA for the detection of autoantibodies to BP230, Clinical Immunology, vol.111, issue.1, pp.146-152, 2004.

N. Ishiura, M. Fujimoto, R. Watanabe, H. Nakashima, Y. Kuwano et al., Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid, Journal of Dermatological Science, vol.49, issue.2, pp.153-161, 2008.

R. Schneiderbauer, S. Martinache, M. Engstner, A. H. Enk, and E. N. Hadaschik, Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid, Dermatologic Therapy, vol.29, issue.6, pp.419-423, 2016.

P. Bernard, C. Bedane, and J. M. Bonnetblanc, Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients, British Journal of Dermatology, vol.136, issue.5, pp.694-698, 1997.

K. Kridin and A. R. Ahmed, Anti-p200 Pemphigoid: A Systematic Review, Frontiers in Immunology, vol.10, p.2466, 2019.

S. Bastuji-garin, P. Joly, P. Lemordant, A. Sparsa, C. Bedane et al., Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case?Control Study, Journal of Investigative Dermatology, vol.131, issue.3, pp.637-643, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00575257

N. Cordel, O. Chosidow, M. Hellot, E. Delaporte, C. Lok et al., Neurological Disorders in Patients with Bullous Pemphigoid, Dermatology, vol.215, issue.3, pp.187-191, 2007.

Y. C. Lai, Y. W. Yew, and W. C. Lambert, Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis, Journal of the European Academy of Dermatology and Venereology, vol.30, issue.12, pp.2007-2015, 2016.

E. Laffitte, P. R. Burkhard, L. Fontao, F. Jaunin, J. Saurat et al., Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis?, British Journal of Dermatology, vol.152, issue.3, pp.537-540, 2005.

J. Chen, L. Li, J. Chen, Y. Zeng, H. Xu et al., Sera of Elderly Bullous Pemphigoid Patients with Associated Neurological Diseases Recognize Bullous Pemphigoid Antigens in the Human Brain, Gerontology, vol.57, issue.3, pp.211-216, 2011.

P. G. Stavropoulos, E. Soura, and C. Antoniou, Drug-induced pemphigoid: a review of the literature, Journal of the European Academy of Dermatology and Venereology, vol.28, issue.9, pp.1133-1140, 2014.

J. J. Lee and T. F. Downham, Furosemide, Reactions Weekly, vol.1748, issue.1, pp.216-216, 2019.

J. Béné, G. Moulis, I. Bennani, M. Auffret, P. Coupe et al., Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database, British Journal of Dermatology, vol.175, issue.2, pp.296-301, 2016.

A. T. Lopez, T. Khanna, N. Antonov, C. Audrey-bayan, and L. Geskin, A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors, International Journal of Dermatology, vol.57, issue.6, pp.664-669, 2018.

L. Vaillant, P. Bernard, P. Joly, C. Prost, B. Labeille et al., Evaluation of Clinical Criteria for Diagnosis of Bullous Pemphigoid, Archives of Dermatology, vol.134, issue.9, p.1075, 1998.

P. Joly, P. H. Courville, C. Lok, P. H. Bernard, P. H. Saiag et al., Clinical Criteria for the Diagnosis of Bullous Pemphigoid: A Reevaluation according to Immunoblot Analysis of Patient Sera, Dermatology, vol.208, issue.1, pp.16-20, 2004.

P. Bernard and F. Antonicelli, Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment, American Journal of Clinical Dermatology, vol.18, issue.4, pp.513-528, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01825913

E. , Pemphigoid diseases, Lancet. 11 déc, vol.381, issue.9863, pp.320-352, 2012.

A. Schwieger-briel, C. Moellmann, B. Mattulat, F. Schauer, D. Kiritsi et al., Bullous pemphigoid in infants: characteristics, diagnosis and treatment, Orphanet Journal of Rare Diseases, vol.9, issue.1, 2014.

D. F. Murrell, B. S. Daniel, P. Joly, L. Borradori, M. Amagai et al., Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts, Bullous pemphigoid in infants: characteristics, diagnosis and treatment, vol.10, pp.479-85, 2012.

P. Courville, I. Kupfer, D. Gilbert, E. Thomine, J. Metayer et al., Evaluation of histological criteria for bullous pemphigoid. Correlation with antigens recognized by immunoblotting of anti-epidermal autoantibodies

, Agutter, Jennifer Ann, (born 20 Dec. 1952), actress, Ann Pathol. déc, vol.20, issue.6, pp.564-573, 2007.

M. Sárdy, D. Kostaki, R. Varga, K. Peris, and T. Ruzicka, Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid, Journal of the American Academy of Dermatology, vol.69, issue.5, pp.748-753, 2013.

P. Machado, H. Michalaki, P. Roche, M. Gaucherand, J. Thivolet et al., Serological diagnosis of bullous pemphigoid (BP): comparison of the sensitivity of indirect immunofluorescence on salt-split to immunoblotting, British Journal of Dermatology, vol.126, issue.3, pp.236-241, 1992.

S. Feng, Q. Wu, P. Jin, L. P. Lin, W. Zhou et al., Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid, International Journal of Dermatology, vol.47, issue.3, pp.225-228, 2008.

A. Roussel, J. Benichou, Z. A. Randriamanantany, D. Gilbert, K. Drenovska et al., Enzyme-Linked Immunosorbent Assay for the Combination of Bullous Pemphigoid Antigens 1 and 2 in the Diagnosis of Bullous Pemphigoid, Archives of Dermatology, vol.147, issue.3, p.293, 2011.

Y. Chan, Y. Sun, N. L. Ng, and S. Tan, Comparison of immunofluorescence microscopy, immunoblotting and enzyme-linked immunosorbent assay methods in the laboratory diagnosis of bullous pemphigoid, Clinical and Experimental Dermatology, vol.28, issue.6, pp.651-656, 2003.

K. Kridin, Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation, British Journal of Dermatology, vol.179, issue.5, pp.1141-1147, 2018.

K. N. Messingham, H. M. Holahan, A. S. Frydman, C. Fullenkamp, R. Srikantha et al., Human Eosinophils Express the High Affinity IgE Receptor, Fc?RI, in Bullous Pemphigoid, PLoS ONE, vol.9, issue.9, p.e107725, 2014.

E. De-graauw, C. Sitaru, M. Horn, L. Borradori, S. Yousefi et al., Evidence for a role of eosinophils in blister formation in bullous pemphigoid, Allergy, vol.72, issue.7, pp.1105-1113, 2017.

J. Fine, Management of Acquired Bullous Skin Diseases, New England Journal of Medicine, vol.333, issue.22, pp.1475-1484, 1995.

N. Korman, Bullous pemphigoid, Journal of the American Academy of Dermatology, vol.16, issue.5, pp.907-924, 1987.

B. Rzany, K. Partscht, M. Jung, W. Kippes, D. Mecking et al., Risk Factors for Lethal Outcome in Patients With Bullous Pemphigoid, Archives of Dermatology, vol.138, issue.7, pp.903-911, 2002.

P. Joly, J. Roujeau, J. Benichou, E. Delaporte, M. D'incan et al., A Comparison of Two Regimens of Topical Corticosteroids in the Treatment of Patients with Bullous Pemphigoid: A Multicenter Randomized Study, Journal of Investigative Dermatology, vol.129, issue.7, pp.1681-1687, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00396990

J. B. Terra, W. J. Potze, and M. F. Jonkman, Whole body application of a potent topical corticosteroid for bullous pemphigoid, Journal of the European Academy of Dermatology and Venereology, vol.28, issue.6, pp.712-718, 2013.

N. Khumalo, G. Kirtschig, P. Middleton, S. Hollis, F. Wojnarowska et al., Interventions for bullous pemphigoid, Cochrane Database Syst Rev, vol.54, issue.3, pp.16-24, 2003.

P. Bernard, C. Bedane, C. Prost, S. Ingen-housz-oro, and P. Joly, Recommandations des centres de référence des maladies bulleuses auto-immunes pour le diagnostic et la prise en charge de la pemphigoïde bulleuse, Annales de Dermatologie et de Vénéréologie, vol.138, issue.3, pp.247-251, 2011.

D. Sur, Graphique 1.1. Croissance annuelle moyenne en pourcentage sur la période 1995-2009 ou dernière période disponible

V. Sobocinski, S. Duvert-lehembre, M. Bubenheim, C. Lesage, P. Bernard et al., Assessment of adherence to topical corticosteroids in patients with bullous pemphigoid, British Journal of Dermatology, vol.174, issue.4, pp.919-921, 2016.

A. Du-thanh, S. Merlet, H. Maillard, P. Bernard, P. Joly et al., Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study, British Journal of Dermatology, vol.165, issue.6, pp.1337-1343, 2011.

P. Kjellman, H. Eriksson, and P. Berg, A Retrospective Analysis of Patients With Bullous Pemphigoid Treated With Methotrexate, Archives of Dermatology, vol.144, issue.5, pp.612-618, 2008.

H. M. Gürcan and A. Razzaque-ahmed, Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid, British Journal of Dermatology, vol.161, issue.4, pp.723-731, 2009.

R. Minkenberg, Result disclosure on ClinicalTrials. gov ? first experiences and challenges, Pharmaceutical Programming, vol.3, issue.2, pp.51-56, 2010.

S. Beissert, T. Werfel, U. Frieling, M. Böhm, M. Sticherling et al., A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid, Archives of Dermatology, vol.143, issue.12, pp.1536-1578, 2007.

M. Böhm, S. Beissert, T. Schwarz, D. Metze, and T. Luger, Bullous pemphigoid treated with mycophenolate mofetil, The Lancet, vol.349, issue.9051, p.541, 1997.

A. Gual, P. Iranzo, and J. M. Mascaró-jr, Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: a case series of 20 patients, Journal of the European Academy of Dermatology and Venereology, vol.28, issue.6, pp.814-818, 2013.

F. Bouscarat, O. Chosidow, C. Picard-dahan, V. Sakiz, B. Crickx et al., Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six cases, Journal of the American Academy of Dermatology, vol.34, issue.4, pp.683-684, 1996.

M. Sticherling, A. Franke, E. Aberer, R. Gläser, M. Hertl et al., An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone, British Journal of Dermatology, vol.177, issue.5, pp.1299-1305, 2017.

D. P. Fivenson, D. L. Breneman, G. B. Rosen, C. S. Hersh, S. Cardone et al., Nicotinamide and Tetracycline Therapy of Bullous Pemphigoid, Archives of Dermatology, vol.130, issue.6, p.753, 1994.

A. Kalinska-bienias, E. Kowalczyk, P. Bienias, K. Gala, P. Jagielski et al., Serum galectin-3 and galectin-3 binding protein levels in systemic lupus erythematosus and cutaneous lupus erythematosus, Advances in Dermatology and Allergology, 2020.

N. Tetracycline and . Lesionally, administered clobetasol as a therapeutic option to prednisone in patients with bullous pemphigoid: a comparative, retrospective analysis of 106 patients with long-term follow-up, Int J Dermatol. févr, vol.58, issue.2, pp.172-179, 2019.

H. C. Williams, F. Wojnarowska, G. Kirtschig, J. Mason, T. R. Godec et al.,

A. Payne, Faculty Opinions recommendation of Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial., Lancet, vol.22, pp.1630-1638, 2017.

M. Amagai, S. Ikeda, T. Hashimoto, M. Mizuashi, A. Fujisawa et al., A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid, Journal of Dermatological Science, vol.85, issue.2, pp.77-84, 2017.

A. R. Ahmed, Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment, Journal of the American Academy of Dermatology, vol.45, issue.6, pp.825-835, 2001.

J. C. Roujeau, P. Morel, E. Dalle, B. Guillot, I. Gorin et al., PLASMA EXCHANGE IN BULLOUS PEMPHIGOID, The Lancet, vol.324, issue.8401, pp.486-489, 1984.

J. C. Guillaume, L. Vaillant, P. Bernard, C. Picard, C. Prost et al., Controlled Trial of Azathioprine and Plasma Exchange in Addition to Prednisolone in the Treatment of Bullous Pemphigoid, Archives of Dermatology, vol.129, issue.1, p.49, 1993.

S. J. Sm, K. , L. , N. , L. et al., Effects of Omalizumab on Fc?RI and IgE Expression in Lesional Skin of, Bullous Pemphigoid. Front Immunol. 14 août, vol.10, pp.1919-1919, 2019.

N. Kremer, I. Snast, E. S. Cohen, E. Hodak, D. Mimouni et al., Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature, American Journal of Clinical Dermatology, vol.20, issue.2, pp.209-216, 2018.

M. Alexandre, G. Bohelay, F. Aucouturier, I. Soued, T. Gille et al., Intérêt de l?omalizumab (OMZ) dans le traitement des pemphigoïdes bulleuses (PB) et pemphigoïdes des muqueuses (PM). Série de 7 cas, Annales de Dermatologie et de Vénéréologie, vol.144, issue.12, p.S88, 2017.

K. K. Yu, A. B. Crew, K. Messingham, J. A. Fairley, and D. T. Woodley, Omalizumab therapy for bullous pemphigoid, J Am Acad Dermatol. sept, vol.71, issue.3, pp.468-74, 2014.

A. Lamberts, H. I. Euverman, J. B. Terra, M. F. Jonkman, B. Horváth et al., First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid, Br J Dermatol. juill, vol.9, issue.1, pp.302-306, 2015.

A. R. Ahmed, S. Shetty, S. Kaveri, and Z. S. Spigelman, Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up, Journal of the American Academy of Dermatology, vol.74, issue.4, pp.700-708.e3, 2016.

N. Berkani, P. Joly, M. Golinski, N. Colliou, A. Lim et al., B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid, Scientific Reports, vol.9, issue.1, p.3525, 2019.

M. Castel, Analyse de la littérature concernant le traitement de la pemphigoïde bulleuse travail préliminaire pour l'actualisation des recommandations nationales sur la pemphigoïde bulleuse, vol.130, 2019.